- Home
- BBUC vs RLAY Comparison
BBUC vs RLAY Comparison
Compare BBUC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBUC | RLAY |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BBUC | RLAY |
|---|---|---|
| Price | $32.40 | $15.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $41.00 | $19.50 |
| AVG Volume (30 Days) | 257.8K | ★ 4.6M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $27.81 | $2.98 |
| 52 Week High | $38.25 | $17.47 |
Technical Indicators
Market Signals| Indicator | BBUC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 59.52 |
| Support Level | $31.38 | $11.68 |
| Resistance Level | $37.44 | $15.45 |
| Average True Range (ATR) | 1.04 | 0.99 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 38.81 | 49.83 |
Price Performance
Historical ComparisonAbout BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.